Protolabs Reports Financial Results for the First Quarter of 2025

Business Wire
05-02

Total Revenue of $126.2 Million

GAAP Earnings Per Share of $0.15, Non-GAAP Earnings Per Share of $0.33

MINNEAPOLIS, May 02, 2025--(BUSINESS WIRE)--Proto Labs, Inc. ("Protolabs" or the "Company") (NYSE: PRLB), the world’s leading provider of digital manufacturing services, today announced financial results for the first quarter ended March 31, 2025.

First Quarter 2025 Financial Highlights:

  • Revenue was $126.2 million, a 1.3% decrease compared to revenue of $127.9 million in the first quarter of 2024.
  • Revenue fulfilled through the Protolabs Network was $26.3 million, a 10.0% increase compared to the first quarter of 2024.
  • Net income was $3.6 million, or $0.15 per diluted share, compared to $5.3 million, or $0.20 per diluted share, in the first quarter of 2024.
  • Non-GAAP net income was $8.1 million, or $0.33 per diluted share, compared to $10.4 million, or $0.40 per diluted share, in the first quarter of 2024. See "Non-GAAP Financial Measures" below.

"Protolabs started the year strong, with revenue and earnings per share near the top of our guidance range and increases in both the number of customers utilizing our combined factory and network offer and spend per customer," said Rob Bodor, President and Chief Executive Officer. "Our first quarter performance establishes a solid foundation for growth in 2025. We are continuing to evolve Protolabs beyond prototyping and into production by enhancing our manufacturing capabilities, unlocking value from our reorganized internal operating structure, and serving our customers more efficiently across the product lifecycle."

"As the tariff landscape evolves, we believe we are well positioned to continue serving our customers through our geographically diverse factory and network fulfillment model," continued Bodor. "Protolabs has a proven track record of adapting faster than anyone to support our customers in times of supply chain disruption, and we are prepared to capitalize on emerging opportunities as the global landscape continues to shift."

Dan Schumacher, Chief Financial Officer, commented: "Our industry-leading profitability and cash flow generation, combined with zero debt on our balance sheet, strongly position us to invest in growth and navigate periods of uncertainty. We continued to return capital to shareholders during the quarter by repurchasing $20.9 million of common stock."

Additional First Quarter 2025 Highlights:

  • Customer contact information
    • Protolabs served 21,627 customer contacts during the quarter.
    • Revenue per customer contact increased 2.5% year-over-year to $5,836.
  • EBITDA was $13.6 million. See "Non-GAAP Financial Measures" below.
  • Adjusted EBITDA was $17.4 million, or 13.8% of revenue, compared to $20.2 million, or 15.8% of revenue, in 2024. See "Non-GAAP Financial Measures" below.
  • Cash and investments balance was $116.3 million as of March 31, 2025.

Second Quarter 2025 Outlook

In the second quarter of 2025, the Company expects to generate revenue between $124.0 million and $132.0 million.

The Company expects second quarter 2025 diluted net income per share between $0.11 and $0.19, and non-GAAP diluted net income per share between $0.30 and $0.38. See "Non-GAAP Financial Measures" below.

Non-GAAP Financial Measures

The Company has included non-GAAP revenue growth by region and by service line that excludes the impact of changes in foreign currency exchange rates (collectively, "non-GAAP revenue growth"). Management believes these metrics, when viewed in conjunction with the comparable GAAP metrics, are useful in evaluating the underlying business trends and ongoing operating performance of the Company.

The Company has included earnings before interest, taxes, depreciation and amortization ("EBITDA") and EBITDA, adjusted for stock-based compensation expense, unrealized (gain) loss on foreign currency and benefits related to exit and disposal activities (collectively, "Adjusted EBITDA"), in this press release to provide investors with additional information regarding the Company’s financial results. The Company has also included earnings before interest, taxes, depreciation and amortization margin ("EBITDA margin") and EBITDA margin, adjusted for stock-based compensation expense, unrealized (gain) loss on foreign currency and benefits related to exit and disposal activities (collectively, "Adjusted EBITDA margin"), in this press release to provide investors with additional information regarding the Company’s financial results.

The Company has included non-GAAP gross margin, adjusted for stock-based compensation expense and amortization expense, in this press release to provide investors with additional information regarding the Company’s financial results.

The Company has included non-GAAP operating margin, adjusted for stock-based compensation expense, amortization expense and benefits related to exit and disposal activities (collectively, "non-GAAP operating margin"), in this press release to provide investors with additional information regarding the Company’s financial results.

The Company has included non-GAAP net income and non-GAAP net income per share, in each case, adjusted for stock-based compensation expense, amortization expense, unrealized (gain) loss on foreign currency and benefits related to exit and disposal activities (collectively, "non-GAAP net income"), in this press release to provide investors with additional information regarding the Company’s financial results.

The Company has provided below reconciliations of GAAP to non-GAAP net income, non-GAAP net income per share, non-GAAP gross margin, non-GAAP operating margin, non-GAAP revenue growth by region and by service line, and Adjusted EBITDA and Adjusted EBITDA margin, the most directly comparable measures calculated and presented in accordance with GAAP. These non-GAAP measures are used by the Company’s management and board of directors to understand and evaluate operating performance and trends, provide useful measures for period-to-period comparisons of the Company’s business, and in determining executive and senior management incentive compensation. Accordingly, the Company believes that these non-GAAP measures provide useful information to investors and others in understanding and evaluating operating results in the same manner as our management and board of directors. These non-GAAP financial measures should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP. These non-GAAP financial measures exclude significant expenses and income that are required by GAAP to be recorded in our condensed consolidated financial statements and are subject to inherent limitations. Investors should review the reconciliations of non-GAAP financial measures to the comparable GAAP financial measures that are included in this press release.

Conference Call

The Company has scheduled a conference call to discuss its first quarter 2025 financial results and second quarter 2025 outlook today, May 2, 2025 at 8:30 a.m. EDT. To access the call in the U.S. please dial 877-709-8150 or outside the U.S. dial 201-689-8354 at least five minutes prior to the 8:30 a.m. EDT start time. No participant code is required. A simultaneous webcast of the call and accompanying presentation will be available via the investor relations section of the Protolabs website and the following link: https://edge.media-server.com/mmc/p/ngihgh3z/. A replay will be available for 14 days following the call on the investor relations section of the Protolabs website.

About Protolabs

Protolabs is the fastest and most comprehensive manufacturing service from prototyping to production. Our digital factories produce low-volume parts in days while Protolabs Network unlocks advanced capabilities and volume pricing through its highly vetted manufacturing partners. The result? One digital manufacturing source for product developers, engineers, and supply chain teams across the globe. See what's next at protolabs.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical or current facts are "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks, uncertainties and other factors which may cause the results of Protolabs to be materially different than those expressed or implied in such statements. Certain of these risk factors and others are described in the "Risk Factors" section within reports filed with the SEC. Other unknown or unpredictable factors also could have material adverse effects on Protolabs’ future results. The forward-looking statements included in this press release are made only as of the date hereof. Protolabs cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, Protolabs expressly disclaims any intent or obligation to update any forward-looking statements to reflect subsequent events or circumstances.

Proto Labs, Inc.

Condensed Consolidated Balance Sheets

(In thousands)

 
 
 

March 31,
2025

December 31,
2024

 

(Unaudited)

Assets

 

Current assets

 

Cash and cash equivalents

 

$

82,692

$

89,071

Short-term marketable securities

 

14,154

14,019

Accounts receivable, net

 

73,904

66,504

Inventory

 

13,202

12,305

Income taxes receivable

 

864

2,906

Prepaid expenses and other current assets

 

9,594

10,049

Total current assets

 

194,410

194,854

 

Property and equipment, net

 

221,207

227,263

Goodwill

 

273,991

273,991

Other intangible assets, net

 

20,775

21,422

Long-term marketable securities

 

19,425

17,773

Operating lease assets

 

2,461

2,993

Finance lease assets

 

625

692

Other long-term assets

 

4,556

4,524

Total assets

 

$

737,450

$

743,512

 

Liabilities and shareholders' equity

 

Current liabilities

 

Accounts payable

 

$

16,288

$

15,504

Accrued compensation

 

18,554

16,550

Accrued liabilities and other

 

24,172

19,621

Current operating lease liabilities

 

1,132

1,287

Current finance lease liabilities

 

312

309

Income taxes payable

 

1,634

Total current liabilities

 

62,092

53,271

 

Long-term operating lease liabilities

 

1,491

1,633

Long-term finance lease liabilities

 

207

287

Long-term deferred tax liabilities

 

12,062

13,565

Other long-term liabilities

 

4,797

4,605

 

Shareholders' equity

 

656,801

670,151

Total liabilities and shareholders' equity

 

$

737,450

$

743,512

 

Proto Labs, Inc.

Condensed Consolidated Statements of Operations

(In thousands, except share and per share amounts)

(Unaudited)

 
 
 

Three Months Ended
March 31,

 

2025

2024

Revenue

 

Injection Molding

 

$

48,723

$

52,663

CNC Machining

 

52,843

49,932

3D Printing

 

20,194

21,582

Sheet Metal

 

4,211

3,553

Other Revenue

 

234

160

Total Revenue

 

126,205

127,890

 

Cost of revenue

 

70,507

70,423

Gross profit

 

55,698

57,467

 

Operating expenses

 

Marketing and sales

 

23,749

23,160

Research and development

 

10,609

11,167

General and administrative

 

16,848

16,313

Benefits related to exit and disposal activities

 

(39

)

Total operating expenses

 

51,167

50,640

Income from operations

 

4,531

6,827

Other income, net

 

1,454

899

Income before income taxes

 

5,985

7,726

Provision for income taxes

 

2,386

2,458

Net income

 

$

3,599

$

5,268

 

Net income per share:

 

Basic

 

$

0.15

$

0.21

Diluted

 

$

0.15

$

0.20

 

Shares used to compute net income per share:

 

Basic

 

24,135,320

25,624,949

Diluted

 

24,435,844

25,784,987

 

Proto Labs, Inc.

Condensed Consolidated Statements of Cash Flows

(In thousands)

(Unaudited)

 
 
 

Three Months Ended
March 31,

 

2025

2024

Operating activities

 

Net income

 

$

3,599

$

5,268

Adjustments to reconcile net income to net cash provided by operating activities:

 

Depreciation and amortization

 

8,694

9,103

Stock-based compensation expense

 

3,992

4,276

Deferred taxes

 

(1,552

)

(2,247

)

Interest on finance lease obligations

 

6

10

Impairments related to exit and closure of facilities

 

219

Gain on disposal of property and equipment

 

(22

)

Other

 

43

63

Changes in operating assets and liabilities

 

3,378

4,887

Net cash provided by operating activities

 

18,379

21,338

 

Investing activities

 

Purchases of property, equipment and other capital assets

 

(1,262

)

(2,587

)

Proceeds from sales of property, equipment and other capital assets

 

22

Purchases of marketable securities

 

(6,552

)

Proceeds from call redemptions and maturities of marketable securities

 

4,905

6,984

Net cash (used in) provided by investing activities

 

(2,909

)

4,419

 

Financing activities

 

Proceeds from issuance of common stock from equity plans

 

287

Purchases of shares withheld for tax obligations

 

(1,248

)

(533

)

Repurchases of common stock

 

(20,890

)

(16,013

)

Principal repayments of finance lease obligations

 

(76

)

(73

)

Net cash used in financing activities

 

(21,927

)

(16,619

)

Effect of exchange rate changes on cash and cash equivalents

 

78

(124

)

Net (decrease) increase in cash and cash equivalents

 

(6,379

)

9,014

Cash and cash equivalents, beginning of period

 

89,071

83,790

Cash and cash equivalents, end of period

 

$

82,692

$

92,804

 

Proto Labs, Inc.

Reconciliation of GAAP to Non-GAAP Net Income and Non-GAAP Net Income per Share

(In thousands, except share and per share amounts)

(Unaudited)

 
 
 

Three Months Ended
March 31,

 

2025

2024

Non-GAAP net income, adjusted for stock-based compensation expense, amortization expense, unrealized (gain) loss on foreign currency and benefits related to exit and disposal activities

 

GAAP net income

 

$

3,599

$

5,268

Add back:

 

Stock-based compensation expense

 

3,992

4,276

Amortization expense

 

908

987

Unrealized (gain) loss on foreign currency

 

(135

)

237

Benefit related to exit and disposal activities

 

(39

)

Total adjustments 1

 

4,726

5,500

Income tax benefits on adjustments 2

 

(242

)

(354

)

Non-GAAP net income

 

$

8,083

$

10,414

 
 

Non-GAAP net income per share:

 

Basic

 

$

0.33

$

0.41

Diluted

 

$

0.33

$

0.40

 

Shares used to compute non-GAAP net income per share:

 

Basic

 

24,135,320

25,624,949

Diluted

 

24,435,844

25,784,987

 

1

 

Stock-based compensation expense, amortization expense, unrealized (gain) loss on foreign currency and benefits related to exit and disposal activities were included in the following GAAP consolidated statement of operations categories:

 

Three Months Ended
March 31,

 

2025

2024

 

Cost of revenue

 

$

802

$

801

 

Marketing and sales

 

778

833

Research and development

 

625

692

General and administrative

 

2,695

2,937

Benefit related to exit and disposal activities

 

(39

)

Total operating expenses

 

4,059

4,462

 

Other income (loss), net

 

(135

)

237

Total adjustments

 

$

4,726

$

5,500

 

2

For the three months ended March 31, 2025 and 2024, income tax effects were calculated using the effective tax rate for the relevant jurisdictions. The Company's non-GAAP tax rates differ from its GAAP tax rates due primarily to the mix of activity incurred in domestic and foreign tax jurisdictions and removing effective tax rate benefits from stock-based compensation activity in the quarter.

 

Proto Labs, Inc.

Reconciliation of GAAP to Non-GAAP Gross Margin

(In thousands)

(Unaudited)

 
 
 

Three Months Ended
March 31,

 

2025

2024

Revenue

 

$

126,205

$

127,890

Gross profit

 

55,698

57,467

GAAP gross margin

 

44.1

%

44.9

%

Add back:

 

Stock-based compensation expense

 

460

459

Amortization expense

 

342

342

Total adjustments

 

802

801

Non-GAAP gross profit

 

$

56,500

$

58,268

Non-GAAP gross margin

 

44.8

%

45.6

%

 

Proto Labs, Inc.

Reconciliation of GAAP to Non-GAAP Operating Margin

(In thousands)

(Unaudited)

 
 
 

Three Months Ended
March 31,

 

2025

2024

Revenue

 

$

126,205

$

127,890

Income from operations

 

4,531

6,827

GAAP operating margin

 

3.6

%

5.3

%

Add back:

 

Stock-based compensation expense

 

3,992

4,276

Amortization expense

 

908

987

Benefit related to exit and disposal activities

 

(39

)

Total adjustments

 

4,861

5,263

Non-GAAP income from operations

 

$

9,392

$

12,090

Non-GAAP operating margin

 

7.4

%

9.5

%

 

Proto Labs, Inc.

Reconciliation of GAAP Net Income to EBITDA and Adjusted EBITDA

(In thousands)

(Unaudited)

 
 
 

Three Months Ended
March 31,

 

2025

2024

Revenue

 

$

126,205

$

127,890

GAAP net income

 

3,599

5,268

GAAP net income margin

 

2.9

%

4.1

%

Add back:

 

Amortization expense

 

$

908

$

987

Depreciation expense

 

7,786

8,116

Interest income, net

 

(1,108

)

(1,112

)

Provision for income taxes

 

2,386

2,458

EBITDA

 

13,571

15,717

EBITDA Margin

 

10.8

%

12.3

%

Add back:

 

Stock-based compensation expense

 

3,992

4,276

Unrealized (gain) loss on foreign currency

 

(135

)

237

Benefit related to exit and disposal activities

 

(39

)

Total adjustments

 

3,818

4,513

Adjusted EBITDA

 

$

17,389

$

20,230

Adjusted EBITDA Margin

 

13.8

%

15.8

%

 

Proto Labs, Inc.

Comparison of GAAP to Non-GAAP Revenue Growth by Region

(In thousands)

(Unaudited)

   
 
 

Three Months Ended
March 31, 2025

Three Months Ended
March 31, 2024

%
Change2

% Change
Organic3

 

GAAP

Foreign

Currency1

Non-GAAP

GAAP

Revenues

 

United States

 

$

100,267

$

$

100,267

$

101,481

(1.2

%)

(1.2

%)

Europe

 

25,938

463

26,401

26,409

(1.8

)

Total revenue

 

$

126,205

$

463

$

126,668

$

127,890

(1.3

%)

(1.0

%)

 

1

 

Revenue for the three months ended March 31, 2025 has been recalculated using 2024 foreign currency exchange rates in effect during comparable periods to provide information useful in evaluating the underlying business trends excluding the impact of changes in foreign currency exchange rates.

2

 

This column presents the percentage change from GAAP revenue for the three months ended March 31, 2024 to GAAP revenue for the three months ended March 31, 2025.

3

 

This column presents the percentage change from GAAP revenue for the three months ended March 31, 2024 to non-GAAP revenue for the three months ended March 31, 2025 (as recalculated using the foreign currency exchange rates in effect during the three months ended March 31, 2024) in order to provide a constant-currency comparison.

 

Proto Labs, Inc.

Comparison of GAAP to Non-GAAP Revenue Growth by Service Line

(In thousands)

(Unaudited)

 
 
 

Three Months Ended
March 31, 2025

Three Months Ended
March 31, 2024

%
Change2

% Change
Organic3

 

GAAP

Foreign
Currency1

Non-GAAP

GAAP

Revenues

 

Injection Molding

 

$

48,723

$

81

$

48,804

$

52,663

(7.5

%)

(7.3

%)

CNC Machining

 

52,843

305

53,148

49,932

5.8

6.4

3D Printing

 

20,194

64

20,258

21,582

(6.4

)

(6.1

)

Sheet Metal

 

4,211

10

4,221

3,553

18.5

18.8

Other Revenue

 

234

3

237

160

46.3

48.1

Total revenue

 

$

126,205

$

463

$

126,668

$

127,890

(1.3

%)

(1.0

%)

1

 

Revenue for the three months ended March 31, 2025 has been recalculated using 2024 foreign currency exchange rates in effect during comparable periods to provide information useful in evaluating the underlying business trends excluding the impact of changes in foreign currency exchange rates.

2

 

This column presents the percentage change from GAAP revenue for the three months ended March 31, 2024 to GAAP revenue for the three months ended March 31, 2025. 

3

 

This column presents the percentage change from GAAP revenue for the three months ended March 31, 2024 to non-GAAP revenue for the three months ended March 31, 2025 (as recalculated using the foreign currency exchange rates in effect during the three months ended March 31, 2024) in order to provide a constant-currency comparison.

 

Proto Labs, Inc.

Customer Contact Information

(In thousands, except customer contacts and per customer contact amounts)

(Unaudited)

 
 
 

Three Months Ended
March 31,

 

2025

2024

Revenue

 

$

126,205

$

127,890

Customer contacts

 

21,627

22,466

Revenue per customer contact1

 

$

5,836

$

5,693

 

1

 

Revenue per customer contact is calculated using the revenue recognized during the respective period divided by the actual number of customer contacts served during the same period. Customer contacts are product developers, engineers, procurement and supply chain professionals and other individuals who place an order, and that order is shipped and invoiced during the period. The Company believes revenue per customer contact is useful to investors in evaluating the underlying business trends and ongoing operating performance of the Company.

     

Proto Labs, Inc.

Reconciliation of GAAP to Non-GAAP Guidance

(Unaudited)

 
 
 

Q2 2025 Outlook

 

Low

High

GAAP diluted net income per share

 

$

0.11

$

0.19

Add back:

 

Stock-based compensation expense

 

0.16

0.16

Amortization expense

 

0.03

0.03

Unrealized (gain) loss on foreign currency

 

0.00

0.00

Total adjustments

 

0.19

0.19

Non-GAAP diluted net income per share

 

$

0.30

$

0.38

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20250502106569/en/

Contacts

Investor Relations Contacts:
Protolabs
Ryan Johnsrud, 612-225-4873
Manager – Investor Relations and FP&A
ryan.johnsrud@protolabs.com



Gateway Group, Inc.
949-574-3860
PRLB@gateway-grp.com

Media Contact:
Protolabs
Brent Renneke, 763-479-7704
Marketing Communications Manager
brent.renneke@protolabs.com



免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10